These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 24798974)

  • 1. Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?
    Byrne JA; Frost S; Chen Y; Bright RK
    Tumour Biol; 2014 Aug; 35(8):7369-82. PubMed ID: 24798974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TPD52 is a Potential Prognostic Biomarker and Correlated with Immune Infiltration: A Pan-cancer Analysis.
    Miao L; Jing L; Chen B; Zeng T; Chen Y
    Curr Mol Med; 2024; 24(11):1413-1425. PubMed ID: 38178662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.
    Byrne JA; Balleine RL; Schoenberg Fejzo M; Mercieca J; Chiew YE; Livnat Y; St Heaps L; Peters GB; Byth K; Karlan BY; Slamon DJ; Harnett P; Defazio A
    Int J Cancer; 2005 Dec; 117(6):1049-54. PubMed ID: 15986428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer.
    Rubin MA; Varambally S; Beroukhim R; Tomlins SA; Rhodes DR; Paris PL; Hofer MD; Storz-Schweizer M; Kuefer R; Fletcher JA; Hsi BL; Byrne JA; Pienta KJ; Collins C; Sellers WR; Chinnaiyan AM
    Cancer Res; 2004 Jun; 64(11):3814-22. PubMed ID: 15172988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-suppressive microRNA-34a inhibits breast cancer cell migration and invasion via targeting oncogenic TPD52.
    Li G; Yao L; Zhang J; Li X; Dang S; Zeng K; Zhou Y; Gao F
    Tumour Biol; 2016 Jun; 37(6):7481-91. PubMed ID: 26678891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells.
    Ummanni R; Teller S; Junker H; Zimmermann U; Venz S; Scharf C; Giebel J; Walther R
    FEBS J; 2008 Nov; 275(22):5703-13. PubMed ID: 18959755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer.
    Wang R; Xu J; Saramäki O; Visakorpi T; Sutherland WM; Zhou J; Sen B; Lim SD; Mabjeesh N; Amin M; Dong JT; Petros JA; Nelson PS; Marshall FF; Zhau HE; Chung LW
    Cancer Res; 2004 Mar; 64(5):1589-94. PubMed ID: 14996714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor protein D52 (isoform 3) interacts with and promotes peroxidase activity of Peroxiredoxin 1 in prostate cancer cells implicated in cell growth and migration.
    Dasari C; Reddy KRK; Natani S; Murthy TRL; Bhukya S; Ummanni R
    Biochim Biophys Acta Mol Cell Res; 2019 Aug; 1866(8):1298-1309. PubMed ID: 30981892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of TPD52 by antitumor microRNA-218 suppresses cancer cell migration and invasion in lung squamous cell carcinoma.
    Kumamoto T; Seki N; Mataki H; Mizuno K; Kamikawaji K; Samukawa T; Koshizuka K; Goto Y; Inoue H
    Int J Oncol; 2016 Nov; 49(5):1870-1880. PubMed ID: 27633630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor protein D52 (isoform 3) contributes to prostate cancer cell growth via targeting nuclear factor-κB transactivation in LNCaP cells.
    Dasari C; Yaghnam DP; Walther R; Ummanni R
    Tumour Biol; 2017 May; 39(5):1010428317698382. PubMed ID: 28466782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. microRNA-218 inhibits prostate cancer cell growth and promotes apoptosis by repressing TPD52 expression.
    Han G; Fan M; Zhang X
    Biochem Biophys Res Commun; 2015 Jan; 456(3):804-9. PubMed ID: 25511701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor protein D52 overexpression and gene amplification in cancers from a mosaic of microarrays.
    Shehata M; Weidenhofer J; Thamotharampillai K; Hardy JR; Byrne JA
    Crit Rev Oncog; 2008; 14(1):33-55. PubMed ID: 19105569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Protein D52 (TPD52) Inhibits Growth and Metastasis in Renal Cell Carcinoma Cells Through the PI3K/Akt Signaling Pathway.
    Zhao Z; Liu H; Hou J; Li T; Du X; Zhao X; Xu W; Xu W; Chang J
    Oncol Res; 2017 May; 25(5):773-779. PubMed ID: 27983909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TPD52 represents a survival factor in ERBB2-amplified breast cancer cells.
    Roslan N; Bièche I; Bright RK; Lidereau R; Chen Y; Byrne JA
    Mol Carcinog; 2014 Oct; 53(10):807-19. PubMed ID: 23661506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA‑103a‑3p promotes metastasis by targeting TPD52 in salivary adenoid cystic carcinoma.
    Fu M; Chen CW; Yang LQ; Yang WW; Du ZH; Li YR; Li SL; Ge XY
    Int J Oncol; 2020 Aug; 57(2):574-586. PubMed ID: 32467999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR.
    Tennstedt P; Bölch C; Strobel G; Minner S; Burkhardt L; Grob T; Masser S; Sauter G; Schlomm T; Simon R
    Int J Oncol; 2014 Feb; 44(2):609-15. PubMed ID: 24317684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor protein D52 (TPD52) affects cancer cell metabolism by negatively regulating AMPK.
    Chen Y; Peng C; Tan W; Yu J; Zayas J; Peng Y; Lou Z; Pei H; Wang L
    Cancer Med; 2023 Jan; 12(1):488-499. PubMed ID: 35666017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
    Byrne JA; Maleki S; Hardy JR; Gloss BS; Murali R; Scurry JP; Fanayan S; Emmanuel C; Hacker NF; Sutherland RL; Defazio A; O'Brien PM
    BMC Cancer; 2010 Sep; 10():497. PubMed ID: 20846453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor protein D52 expression is post-transcriptionally regulated by T-cell intercellular antigen (TIA) 1 and TIA-related protein via mRNA stability.
    Motohashi H; Mukudai Y; Ito C; Kato K; Shimane T; Kondo S; Shirota T
    Biochem J; 2017 May; 474(10):1669-1687. PubMed ID: 28298474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical support for tumor protein D52 as a cancer vaccine antigen.
    Bright RK
    Hum Vaccin Immunother; 2023 Dec; 19(3):2273699. PubMed ID: 37904517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.